SRPK2 and cancer: A range of preclinical studies was included, generally addressing four main aspects: cancer-related signalling pathways involving SRPK2; its prognostic associations; its impact on metastatic and/or tumour phenotypes; and the antitumor and/or antimetastatic effects resulting from its inhibition.